News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation and Eli Lilly and Company (LLY) Release: Trajenta┬« (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe


8/25/2011 10:25:29 AM

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorisation from the European Commission for Trajenta® (linagliptin) 5 mg film-coated tablets for the treatment of adults with type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulphonylurea.1 Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.1

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES